Obesity
Conditions
Brief summary
This studay evaluates the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist,including Liraglutide,Exenatide and Exenatide Microspheres for Injection,in the treatment of subjects who are overweight or obese.
Interventions
DRUGLiraglutide
The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
DRUGExenatide
10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.
DRUGExenatide Microspheres for Injection
Exenatide 2 mg injection once weekly for 12 weeks.
Sponsors
Xiangya Hospital of Central South University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Patients aged 18 to 65 years (to the date of screening)； 2. The newly diagnosed obese patients (BMI greater than 28 kg/m2) or abdominal obesity (male waist circumference is greater than 90cm, female waist is greater than 85cm). 3. Nearly a month have not used weight-related drugs,including various weight-loss drugs,GLP-1 analogs or agonists,metformin, acarbose,insulin,anti hyperthyroid drugs,etc;Or recently used weight-related drugs but the stable dose was more than 1 month,and the drug dose remained constant or decreased during the trial. 4. Weight stable for more than 3 months (weight fluctuations \<5%).
Exclusion criteria
1. pregnant female. 2. Secondary diseases caused by other diseases: including hypothyroidism, increased cortisol, hypothalamic and pituitary lesions caused by obesity, all kinds of drug-induced obesity, and others. 3. Severe cardiovascular and cerebrovascular diseases (heart failure, myocardial infarction, acute hemorrhagic or ischemic encephalopathy), pulmonary heart disease or pulmonary insufficiency, renal failure, severe hepatitis. 4. Combined with acute complications of diabetes such as ketoacidosis, lactic acidosis, hyperosmolar state of diabetes. 5. Nearly a month had surgery, trauma, infection and so on. 6. Limb deformity incomplete, difficult to accurately determine the height, weight and other physical indicators. 7. Poor medication compliance or serious side effects (severe rash, syncope, etc.).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Weight Change at 3 months | baseline , 3 months | Measured in kilograms |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in systolic blood pressure | baseline and 3 months | Measured in mmHg |
| Change in diastolic blood pressure | baseline and 3 months | Measured in mmHg |
| Change in HbA1c | baseline and 3 months | Measured in % |
| Change in plasma glucose | baseline and 3 months | Measured in mmol/l |
| Change in insulin | baseline and 3 months | Measured in μU/ml |
| Change in lipids-total cholesterol | baseline and 3 months | Measured in mmol/l |
| Change in waist circumference | baseline and 3 months | Measured in cm |
| Change in lipids-high density lipoprotein cholesterol | baseline and 3 months | Measured in mmol/l |
| Change in lipids-triglycerides | baseline and 3 months | Measured in mmol/l |
| Change in lipids-free fatty acids | baseline and 3 months | Measured in μmol/l |
| Change in Uric Acid | baseline and 3 months | Measured in mmol/l |
| Change in interleukin-6 | baseline and 3 months | Measured in mmol/l |
| Change in tumor necrosis factor | baseline and 3 months | Measured in mmol/l |
| Change in lipids-low density lipoprotein cholesterol | baseline and 3 months | Measured in mmol/l |
Countries
China
Contacts
Primary ContactJing Wu
Outcome results
None listed